XPAR:DIM (Germany)
Business Description
Sartorius Stedim Biotech SA
NAICS : 334510
SIC : 3844
Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Compare
Compare
Traded in other countries / regions
DIM.Austria
•
DIM.France
•
56S1.Germany
•
DIM.Mexico
•
0RG8.UK
•
SDMHF.USA
Description
Sartorius Stedim Biotech is the leading provider of tools for biopharmaceutical fermentation and fluid management. Parent Sartorius AG has a 74% stake in the company, with 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (40% of 2020 sales), the Americas (35%), and Asia-Pacific (25%). Sartorius Stedim Biotech employs over 7,500 people and has operations in more than 20 countries.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.36 | |||||
| Debt-to-EBITDA | 0.71 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 11.35 | |||||
| Beneish M-Score | -2.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 33.5 | |||||
| 3-Year EBITDA Growth Rate | 31.7 | |||||
| 3-Year EPS without NRI Growth Rate | 25.8 | |||||
| 3-Year FCF Growth Rate | 139.3 | |||||
| 3-Year Book Growth Rate | 16.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 9.58 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 19.64 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.36 | |||||
| 9-Day RSI | 58.53 | |||||
| 14-Day RSI | 60.32 | |||||
| 6-1 Month Momentum % | -6.13 | |||||
| 12-1 Month Momentum % | -29.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | |||||
| Quick Ratio | 0.63 | |||||
| Cash Ratio | 0.16 | |||||
| Days Inventory | 185.03 | |||||
| Days Sales Outstanding | 41.89 | |||||
| Days Payable | 100.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.33 | |||||
| Dividend Payout Ratio | 0.19 | |||||
| 3-Year Dividend Growth Rate | 13.9 | |||||
| Forward Dividend Yield % | 0.33 | |||||
| 5-Year Yield-on-Cost % | 0.52 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.69 | |||||
| Operating Margin % | 30.29 | |||||
| Net Margin % | 19.66 | |||||
| ROE % | 35.73 | |||||
| ROA % | 16.03 | |||||
| ROIC % | 22.2 | |||||
| ROC (Joel Greenblatt) % | 71.41 | |||||
| ROCE % | 29.09 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 54.86 | |||||
| Forward PE Ratio | 43.29 | |||||
| PE Ratio without NRI | 53.94 | |||||
| Shiller PE Ratio | 178.98 | |||||
| Price-to-Owner-Earnings | 128.26 | |||||
| PEG Ratio | 2.14 | |||||
| PS Ratio | 10.79 | |||||
| PB Ratio | 17.13 | |||||
| Price-to-Tangible-Book | 68.09 | |||||
| Price-to-Free-Cash-Flow | 109.1 | |||||
| Price-to-Operating-Cash-Flow | 61.18 | |||||
| EV-to-EBIT | 40.81 | |||||
| EV-to-Forward-EBIT | 32.64 | |||||
| EV-to-EBITDA | 34.47 | |||||
| EV-to-Forward-EBITDA | 29.35 | |||||
| EV-to-Revenue | 10.95 | |||||
| EV-to-Forward-Revenue | 10.18 | |||||
| EV-to-FCF | 108.79 | |||||
| Price-to-Projected-FCF | 10.8 | |||||
| Price-to-DCF (Earnings Based) | 1.44 | |||||
| Price-to-DCF (FCF Based) | 2.87 | |||||
| Price-to-Median-PS-Value | 0.82 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.19 | |||||
| Price-to-Graham-Number | 12.88 | |||||
| Earnings Yield (Greenblatt) % | 2.46 | |||||
| Forward Rate of Return (Yacktman) % | 20.58 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,259.477 | ||
| EPS (TTM) (€) | 6.95 | ||
| Beta | 0.02 | ||
| Volatility % | 47.09 | ||
| 14-Day RSI | 60.32 | ||
| 14-Day ATR (€) | 13.494901 | ||
| 20-Day SMA (€) | 370.505 | ||
| 12-1 Month Momentum % | -29.94 | ||
| 52-Week Range (€) | 268.6 - 551 | ||
| Shares Outstanding (Mil) | 92.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sartorius Stedim Biotech SA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||